EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival

被引:80
|
作者
Xia, G
Kumar, SP
Stein, JP
Singh, J
Krasnoperov, V
Zhu, S
Hassanieh, L
Smith, DL
Buscarini, M
Broek, D
Quinn, DI
Weaver, FA
Gill, PS
机构
[1] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA
[2] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA USA
[3] Univ So Calif, Keck Sch Med, Dept Surg, Los Angeles, CA USA
[4] Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA USA
[5] VasGene Therapeut Inc, Los Angeles, CA USA
[6] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA USA
关键词
receptor tyrosine kinase; bladder cancer; cell growth; EphB4;
D O I
10.1038/sj.onc.1209108
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We sought to evaluate the biological function of the receptor tyrosine kinase EphB4 in bladder cancer. All of the nine bladder cancer cell lines examined express EphB4 and the receptor could be phosphorylated following stimulation with its cognate ligand, EphrinB2. Out of the 15 fresh bladder cancer specimens examined, 14 expressed EphB4 with a mean sevenfold higher level of expression compared to adjacent normal urothelium. EphB4 expression was regulated by several mechanisms: EPHB4 gene locus was amplified in 27% tumor specimens and 33% cell lines studied; inhibition of EGFR signaling downregulated EphB4 levels; and forced expression of wild-type p53 reduced EphB4 expression. EphB4 knockdown using specific siRNA and antisense oligodeoxynucleotides molecules led to a profound inhibition in cell viability associated with apoptosis via activation of caspase-8 pathway and downregulation of anti apoptotic factor, bcl-xl. Furthermore, EphB4 knockdown significantly inhibited tumor cell migration and invasion. EphB4 knockdown in an in vivo murine tumor xenograft model led to a nearly 80% reduction in tumor volume associated with reduced tumor proliferation, increased apoptosis and reduced tumor microvasculature. EphB4 is thus a potential candidate as a predictor of disease outcome in bladder cancer and as target for novel therapy.
引用
收藏
页码:769 / 780
页数:12
相关论文
共 50 条
  • [21] The Receptor Tyrosine Kinase EPHB4 Has Tumor Suppressor Activities in Intestinal Tumorigenesis
    Dopeso, Higinio
    Mateo-Lozano, Silvia
    Mazzolini, Rocco
    Rodrigues, Paulo
    Lagares-Tena, Laura
    Ceron, Julian
    Romero, Jordi
    Esteves, Marielle
    Landolfi, Stefania
    Hernandez-Losa, Javier
    Castano, Julio
    Wilson, Andrew J.
    Ramon Y Cajal, Santiago
    Mariadason, John M.
    Schwartz, Simo, Jr.
    Arango, Diego
    CANCER RESEARCH, 2009, 69 (18) : 7430 - 7438
  • [22] The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis
    Dopeso, Higinio
    -Lozano, Silvia Mateo
    Davalos, Veronica
    Mazzolini, Rocco
    Rodrigues, Paulo
    Lagares-Tena, Laura
    Ceron, Julian
    Romero, Jordi
    Vilardell, Felip
    Landolfi, Stefania
    Hernandez-Losa, Javier
    Wilson, Andrew J.
    Cajal, Santiago Ramon y
    Capella, Gabriel
    Aaltonen, Lauri A.
    Mariadason, John M.
    Schwartz, Simo, Jr.
    Diego, Arango
    CANCER RESEARCH, 2010, 70
  • [23] The receptor tyrosine kinase, EphB4 (HTK), promotes megakaryocytic and erythroid differentiation.
    Wang, ZY
    Miura, N
    Bonelli, A
    Mole, P
    Scadden, DT
    BLOOD, 2000, 96 (11) : 129B - 129B
  • [24] Differential regulation of EPHB4 and EPH132 receptor tyrosine kinases in normal bladder and bladder transitional cell carcinoma
    Choi, Wesley W.
    Scehnet, Jeff S.
    Kumar, S. Ram
    Lee, Charlotte C.
    Schuckman, Anne
    Klumpp, David J.
    Stein, John P.
    Gill, Parkash S.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 256 - 256
  • [25] Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma
    Berclaz, G
    Karamitopoulou, E
    Mazzucchelli, L
    Rohrbach, V
    Dreher, E
    Ziemiecki, A
    Andres, AC
    ANNALS OF ONCOLOGY, 2003, 14 (02) : 220 - 226
  • [26] EPHB4 and survival of colorectal cancer patients
    Davalos, Veronica
    Dopeso, Higinio
    Castano, Julio
    Wilson, Andrew J.
    Vilardell, Felip
    Romero-Gimenez, Jordi
    Espin, Eloy
    Armengol, Manel
    Capella, Gabriel
    Mariadason, John M.
    Aaltonen, Lauri A.
    Schwartz, Simo, Jr.
    Arango, Diego
    CANCER RESEARCH, 2006, 66 (18) : 8943 - 8948
  • [27] The Differential Expression of EphB2 and EphB4 Receptor Kinases in Normal Bladder and in Transitional Cell Carcinoma of the Bladder
    Li, Xiuqing
    Choi, Wesley W.
    Yan, Rui
    Yu, Haiyang
    Krasnoperov, Valery
    Kumar, S. Ram
    Schuckman, Anne
    Klumpp, David J.
    Pan, Chong-Xian
    Quinn, David
    Gill, Inderbir S.
    Gill, Parkash S.
    Liu, Ren
    PLOS ONE, 2014, 9 (08):
  • [28] Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast
    Berclaz, G
    Flütsch, B
    Altermatt, HJ
    Rohrbach, V
    Djonov, V
    Ziemiecki, A
    Dreher, E
    Andres, AC
    ONCOLOGY REPORTS, 2002, 9 (05) : 985 - 989
  • [29] Receptor tyrosine kinase, EphB4 (HTK), accelerates differentiation of select human hematopoietic cells
    Wang, ZY
    Miura, N
    Bonelli, A
    Mole, P
    Carlesso, N
    Olson, DP
    Scadden, DT
    BLOOD, 2002, 99 (08) : 2740 - 2747
  • [30] EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma
    Becerikli, M.
    Merwart, B.
    Lam, M. C.
    Suppelna, P.
    Rittig, A.
    Mirmohammedsadegh, A.
    Stricker, I.
    Theiss, C.
    Singer, B. B.
    Jacobsen, F.
    Steinstraesser, L.
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (08) : 1781 - 1791